

**Supplementary Table 3. Results of Subgroup Analysis Regarding Whether Only MRI Was Used as an Imaging Modality or Not**

Outcomes	Studies Using MRI Only			Studies Using CT and MRI			P
	No. of Studies	Proportion (%)	Meta-Analytic Proportion (95% CI)	No. of Studies	Proportion (%)	Meta-Analytic Proportion (95% CI)	
<b>Cohort-based outcomes</b>							
Patients with neurologic symptoms/all patients	2	358/1411 (25)	24.3 (19.9–29.4)	2	57/130 (44)	45.1 (26.9–64.7)	0.004
Patients with neuroimaging/patients with neurologic symptoms	2	100/358 (28)	37.1 (13.8–68.4)	2	57/57 (100)	98.3 (88.9–99.8)	< 0.001
Patients with neuroimaging/all patients	4	274/8876 (3)	3.4 (2.1–5.4)	6	912/9097 (10)	18.5 (11.0–29.3)	< 0.001
Patients with any neuroimaging findings/patients with neuroimaging	3	176/247 (71)	72.8 (56.8–84.5)	2	43/57 (75)	76.0 (53.2–89.8)	0.793
Patients with neuroimaging findings related to COVID-19*/patients with neuroimaging	4	102/265 (38)	40.1 (28.0–53.6)	4	112/485 (23)	31.1 (16.6–50.6)	0.397
Patients with neuroimaging findings related to COVID-19*/all patients	3	66/7700 (1)	0.9 (0.6–1.4)	4	112/2825 (4)	8.4 (2.8–22.2)	0.002
<b>Neuroimaging findings</b>							
Olfactory bulb abnormality	0	-	-	2	11/49 (22)	23.1 (12.9–37.7)	-
White matter abnormality	4	50/274 (18)	17.0 (7.7–33.4)	2	29/191 (15)	19.4 (1.1–84.2)	0.862
Acute or subacute ischemic infarction	5	59/250 (24)	24.4 (16.1–35.2)	5	71/739 (10)	11.0 (6.8–17.2)	0.011
Encephalopathy	3	11/141 (8)	7.5 (2.3–21.7)	5	47/291 (16)	17.7 (4.3–50.8)	0.383
Cerebral microbleeds	4	42/274 (15)	14.5 (7.4–26.4)	4	65/709 (9)	10.7 (1.7–45.9)	0.853
Intracranial hemorrhage	1	4/27 (15)	-	5	43/739 (6)	6.9 (2.9–15.6)	0.473
Others	3	33/164 (20)	15.4 (5.1–38.2)	2	5/308 (2)	2.6 (0.4–14.3)	0.066
Venous thrombosis	1	2/30 (7)	-	1	1/27 (4)	-	NA
PRES	1	2/73 (3)	-	1	3/278 (1)	-	NA
Grey matter abnormality	2	11/86 (13)	10.2 (0.4–78.2)	0	-	-	-
Cranial neuropathy other than olfactory nerves	1	2/73 (3)	-	2	4/298 (1)	2.7 (0.2–29.0)	0.999

\*Excluding neuroimaging findings not likely to be related to COVID-19, including cavernoma, chronic infarcts, known white matter lesions from multiple sclerosis, white matter lesions of small vessel disease, and microbleeds associated with chronic infarction. CI = confidence interval, COVID-19 = coronavirus disease 2019, NA = not available, PRES = posterior reversible encephalopathy syndrome